8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 7 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.62, a high estimate of $75.00, and a low estimate of $51.00. This current average reflects an increase of 3.26% from the previous average price target of $54.83.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of Agios Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Raises | Outperform | $57.00 | $55.00 |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $75.00 | $53.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $55.00 | $55.00 |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $53.00 | $51.00 |
| Greg Harrison | Scotiabank | Announces | Sector Outperform | $51.00 | - |
| Danielle Brill | Raymond James | Announces | Outperform | $51.00 | - |
| Andrew Berens | Leerink Partners | Lowers | Market Perform | $56.00 | $60.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $55.00 | $55.00 |
Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agios Pharmaceuticals compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agios Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Agios Pharmaceuticals analyst ratings.
About Agios Pharmaceuticals
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Key Indicators: Agios Pharmaceuticals's Financial Health
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10574.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 82.89%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Agios Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 73.92%. This signifies efficient management of assets and strong financial health.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for AGIO
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Goldman Sachs | Maintains | Sell | |
| Mar 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Feb 2022 | RBC Capital | Maintains | Outperform |
View More Analyst Ratings for AGIO
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
